Skip to main content
Erschienen in: Current Rheumatology Reports 1/2012

01.02.2012 | SCLERODERMA (J VARGA, SECTION EDITOR)

Angiogenesis and Vasculopathy in Systemic Sclerosis: Evolving Concepts

verfasst von: Bradley J. Rabquer, Alisa E. Koch

Erschienen in: Current Rheumatology Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Systemic sclerosis (scleroderma [SSc]) is a multifactorial disease characterized by inflammation, extensive and progressive fibrosis, and multiple vasculopathies. The vascular manifestations can be seen early in the pathogenesis of the disease and include malformed capillaries, Raynaud’s phenomenon, and digital ulcers. As the disease progresses, the vasculopathy proceeds to significant clinical manifestations, including renal crisis and pulmonary arterial hypertension. Moreover, later stages of the disease are marked by increasingly avascular areas. Despite the obliteration of microvascular structures, compensatory vasculogenesis and angiogenesis do not occur normally. This is in spite of a general increase in many potent angiogenic factors. Recent studies are beginning to examine this paradox and subsequent paucity of an angiogenic response in SSc. In this review, we discuss these findings and examine the role that chemokine and growth factor receptors, proteases, adhesion molecules, and transcription factors play in the dysregulation of angiogenesis in SSc.
Literatur
1.
Zurück zum Zitat • Gabrielli A, Avvedimento EV, Krieg T: Scleroderma. N Engl J Med 2009, 360(19):1989–2003. This is an excellent recent review on the pathogenesis of SSc. PubMedCrossRef • Gabrielli A, Avvedimento EV, Krieg T: Scleroderma. N Engl J Med 2009, 360(19):1989–2003. This is an excellent recent review on the pathogenesis of SSc. PubMedCrossRef
3.
Zurück zum Zitat Lambova SN, Muller-Ladner U. Capillaroscopic pattern in systemic sclerosis—an association with dynamics of processes of angio- and vasculogenesis. Microvasc Res. 2010;80(3):534–9.PubMedCrossRef Lambova SN, Muller-Ladner U. Capillaroscopic pattern in systemic sclerosis—an association with dynamics of processes of angio- and vasculogenesis. Microvasc Res. 2010;80(3):534–9.PubMedCrossRef
4.
Zurück zum Zitat Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol. 2007;34(12):2423–30.PubMed Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol. 2007;34(12):2423–30.PubMed
5.
Zurück zum Zitat Lambova S, Muller-Ladner U. Pulmonary arterial hypertension in systemic sclerosis. Autoimmun Rev. 2010;9(11):761–70.PubMedCrossRef Lambova S, Muller-Ladner U. Pulmonary arterial hypertension in systemic sclerosis. Autoimmun Rev. 2010;9(11):761–70.PubMedCrossRef
6.
Zurück zum Zitat Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182(2):252–60.PubMedCrossRef Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182(2):252–60.PubMedCrossRef
7.
Zurück zum Zitat Denton CP, Lapadula G, Mouthon L, Muller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009;48 Suppl 3:iii32–5.CrossRef Denton CP, Lapadula G, Mouthon L, Muller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009;48 Suppl 3:iii32–5.CrossRef
8.
Zurück zum Zitat Au K, Singh MK, Bodukam V et al.: Atherosclerosis in systemic sclerosis—a systematic review and meta analysis. Arthritis Rheum 2011, Epub ahead of print. Au K, Singh MK, Bodukam V et al.: Atherosclerosis in systemic sclerosis—a systematic review and meta analysis. Arthritis Rheum 2011, Epub ahead of print.
9.
Zurück zum Zitat Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000;95(3):952–8.PubMed Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000;95(3):952–8.PubMed
10.
Zurück zum Zitat Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med. 2010;14(6A):1241–54.PubMedCrossRef Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med. 2010;14(6A):1241–54.PubMedCrossRef
11.
Zurück zum Zitat Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet. 2004;364(9434):603–10.PubMedCrossRef Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet. 2004;364(9434):603–10.PubMedCrossRef
12.
Zurück zum Zitat Allanore Y, Batteux F, Avouac J, et al. Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol. 2007;25(1):60–6.PubMed Allanore Y, Batteux F, Avouac J, et al. Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol. 2007;25(1):60–6.PubMed
13.
Zurück zum Zitat Avouac J, Juin F, Wipff J, et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis. 2008;67(10):1455–60.PubMedCrossRef Avouac J, Juin F, Wipff J, et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis. 2008;67(10):1455–60.PubMedCrossRef
14.
Zurück zum Zitat Del Papa N, Quirici N, Soligo D, et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 2006;54(8):2605–15.PubMedCrossRef Del Papa N, Quirici N, Soligo D, et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 2006;54(8):2605–15.PubMedCrossRef
15.
Zurück zum Zitat Distler JH, Allanore Y, Avouac J, et al. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis. 2009;68(2):163–8.PubMedCrossRef Distler JH, Allanore Y, Avouac J, et al. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis. 2009;68(2):163–8.PubMedCrossRef
16.
Zurück zum Zitat Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95(4):343–53.PubMedCrossRef Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95(4):343–53.PubMedCrossRef
17.
Zurück zum Zitat Jujo K, Ii M, Losordo DW. Endothelial progenitor cells in neovascularization of infarcted myocardium. J Mol Cell Cardiol. 2008;45(4):530–44.PubMedCrossRef Jujo K, Ii M, Losordo DW. Endothelial progenitor cells in neovascularization of infarcted myocardium. J Mol Cell Cardiol. 2008;45(4):530–44.PubMedCrossRef
18.
Zurück zum Zitat •• Yamaguchi Y, Okazaki Y, Seta N et al.: Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Res Ther 2010, 12(6):R205. This was the first study to describe monocytic EPCs in SSc. The report further demonstrates that vasculogenesis is impaired in SSc and shows how monocytic EPCs may play a role in angiogenesis. PubMedCrossRef •• Yamaguchi Y, Okazaki Y, Seta N et al.: Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Res Ther 2010, 12(6):R205. This was the first study to describe monocytic EPCs in SSc. The report further demonstrates that vasculogenesis is impaired in SSc and shows how monocytic EPCs may play a role in angiogenesis. PubMedCrossRef
19.
Zurück zum Zitat Kaminski MJ, Majewski S, Jablonska S, Pawinska M. Lowered angiogeneic capability of peripheral blood lymphocytes in progressive systemic sclerosis (scleroderma). J Invest Dermatol. 1984;82(3):239–43.PubMedCrossRef Kaminski MJ, Majewski S, Jablonska S, Pawinska M. Lowered angiogeneic capability of peripheral blood lymphocytes in progressive systemic sclerosis (scleroderma). J Invest Dermatol. 1984;82(3):239–43.PubMedCrossRef
20.
Zurück zum Zitat Majewski S, Skopinska-Rozewska E, Jablonska S, et al. Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. Arthritis Rheum. 1985;28(10):1133–9.PubMedCrossRef Majewski S, Skopinska-Rozewska E, Jablonska S, et al. Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. Arthritis Rheum. 1985;28(10):1133–9.PubMedCrossRef
21.
Zurück zum Zitat Koch AE, Polverini PJ, Leibovich SJ. Induction of neovascularization by activated human monocytes. J Leukoc Biol. 1986;39:233–8.PubMed Koch AE, Polverini PJ, Leibovich SJ. Induction of neovascularization by activated human monocytes. J Leukoc Biol. 1986;39:233–8.PubMed
22.
Zurück zum Zitat Marczak M, Majewski S, Skopinska-Rozewska E, et al. Enhanced angiogenic capability of monocyte-enriched mononuclear cell suspensions from patients with systemic scleroderma. J Invest Dermatol. 1986;86(4):355–8.PubMedCrossRef Marczak M, Majewski S, Skopinska-Rozewska E, et al. Enhanced angiogenic capability of monocyte-enriched mononuclear cell suspensions from patients with systemic scleroderma. J Invest Dermatol. 1986;86(4):355–8.PubMedCrossRef
23.
Zurück zum Zitat Kahaleh MB, DeLustro F, Bock W, LeRoy EC. Human monocyte modulation of endothelial cells and fibroblast growth: possible mechanism for fibrosis. Clin Immunol Immunopathol. 1986;39(2):242–55.PubMedCrossRef Kahaleh MB, DeLustro F, Bock W, LeRoy EC. Human monocyte modulation of endothelial cells and fibroblast growth: possible mechanism for fibrosis. Clin Immunol Immunopathol. 1986;39(2):242–55.PubMedCrossRef
24.
Zurück zum Zitat Liakouli V, Cipriani P, Marrelli A et al.: Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011. Liakouli V, Cipriani P, Marrelli A et al.: Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011.
25.
Zurück zum Zitat •• Margheri F, Serrati S, Lapucci A et al.: Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12. Arthritis Rheum 2010, 62(8):2488–2498. This excellent study expanded on the observation that MMP-12 and pentraxin 3 are overexpressed in SSc by performing an in vitro analysis of their role in angiogenesis. The authors showed that overexpressing both molecules in healthy ECs resulted in an inhibition of angiogenesis. They also found that SSc ECs do not mount an angiogenic response to bFGF or VEGF. PubMedCrossRef •• Margheri F, Serrati S, Lapucci A et al.: Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12. Arthritis Rheum 2010, 62(8):2488–2498. This excellent study expanded on the observation that MMP-12 and pentraxin 3 are overexpressed in SSc by performing an in vitro analysis of their role in angiogenesis. The authors showed that overexpressing both molecules in healthy ECs resulted in an inhibition of angiogenesis. They also found that SSc ECs do not mount an angiogenic response to bFGF or VEGF. PubMedCrossRef
26.
Zurück zum Zitat Mackiewicz Z, Sukura A, Povilenaite D, et al. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol. 2002;20(5):641–6.PubMed Mackiewicz Z, Sukura A, Povilenaite D, et al. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol. 2002;20(5):641–6.PubMed
27.
Zurück zum Zitat Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004;95(1):109–16.PubMedCrossRef Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004;95(1):109–16.PubMedCrossRef
28.
Zurück zum Zitat Davies CA, Jeziorska M, Freemont AJ, Herrick AL. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol. 2006;37(2):190–7.PubMedCrossRef Davies CA, Jeziorska M, Freemont AJ, Herrick AL. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol. 2006;37(2):190–7.PubMedCrossRef
29.
Zurück zum Zitat Carulli MT, Ong VH, Ponticos M, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum. 2005;52(12):3772–82.PubMedCrossRef Carulli MT, Ong VH, Ponticos M, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum. 2005;52(12):3772–82.PubMedCrossRef
30.
Zurück zum Zitat • Rabquer BJ, Tsou P, Hou Y et al.: Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 2011, 13(1):R18. This study provides further evidence of the importance of determining the expression of both angiogenic mediators and their receptors. It demonstrated that while antiangiogenic chemokines are elevated in SSc, their receptor is downregulated, thus limiting their impact. PubMedCrossRef • Rabquer BJ, Tsou P, Hou Y et al.: Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 2011, 13(1):R18. This study provides further evidence of the importance of determining the expression of both angiogenic mediators and their receptors. It demonstrated that while antiangiogenic chemokines are elevated in SSc, their receptor is downregulated, thus limiting their impact. PubMedCrossRef
31.
Zurück zum Zitat Cipriani P, Franca Milia A, Liakouli V, et al. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis Rheum. 2006;54(9):3022–33.PubMedCrossRef Cipriani P, Franca Milia A, Liakouli V, et al. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis Rheum. 2006;54(9):3022–33.PubMedCrossRef
32.
Zurück zum Zitat Rabquer BJ, Boychev G, Ruth JH, et al. Soluble junctional adhesion molecule-A promotes angiogenesis in rheumatoid arthritis. Arthritis Rheum. 2010;62:S590.CrossRef Rabquer BJ, Boychev G, Ruth JH, et al. Soluble junctional adhesion molecule-A promotes angiogenesis in rheumatoid arthritis. Arthritis Rheum. 2010;62:S590.CrossRef
33.
Zurück zum Zitat Hou Y, Rabquer BJ, Gerber ML, et al. Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion. Ann Rheum Dis. 2009;69(1):249–54.CrossRef Hou Y, Rabquer BJ, Gerber ML, et al. Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion. Ann Rheum Dis. 2009;69(1):249–54.CrossRef
34.
Zurück zum Zitat Naik MU, Mousa SA, Parkos CA, Naik UP. Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex. Blood. 2003;102(6):2108–14.PubMedCrossRef Naik MU, Mousa SA, Parkos CA, Naik UP. Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex. Blood. 2003;102(6):2108–14.PubMedCrossRef
35.
Zurück zum Zitat D’Alessio S, Fibbi G, Cinelli M, et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum. 2004;50(10):3275–85.PubMedCrossRef D’Alessio S, Fibbi G, Cinelli M, et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum. 2004;50(10):3275–85.PubMedCrossRef
36.
Zurück zum Zitat Giusti B, Fibbi G, Margheri F, et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther. 2006;8(4):R115.PubMedCrossRef Giusti B, Fibbi G, Margheri F, et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther. 2006;8(4):R115.PubMedCrossRef
37.
Zurück zum Zitat Serrati S, Cinelli M, Margheri F, et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol. 2006;210(2):240–8.PubMedCrossRef Serrati S, Cinelli M, Margheri F, et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol. 2006;210(2):240–8.PubMedCrossRef
38.
Zurück zum Zitat Manetti M, Allanore Y, Revillod L, et al. A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. Arthritis Rheum. 2011;63(1):247–56.PubMedCrossRef Manetti M, Allanore Y, Revillod L, et al. A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. Arthritis Rheum. 2011;63(1):247–56.PubMedCrossRef
39.
Zurück zum Zitat Dean RA, Cox JH, Bellac CL, et al. Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR + CXC chemokines and generates CCL2, −7, −8, and −13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood. 2008;112(8):3455–64.PubMedCrossRef Dean RA, Cox JH, Bellac CL, et al. Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR + CXC chemokines and generates CCL2, −7, −8, and −13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood. 2008;112(8):3455–64.PubMedCrossRef
40.
Zurück zum Zitat Giusti B, Serrati S, Margheri F, et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum. 2005;52(11):3618–28.PubMedCrossRef Giusti B, Serrati S, Margheri F, et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum. 2005;52(11):3618–28.PubMedCrossRef
41.
Zurück zum Zitat Margheri F, Manetti M, Serrati S, et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 2006;54(12):3926–38.PubMedCrossRef Margheri F, Manetti M, Serrati S, et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 2006;54(12):3926–38.PubMedCrossRef
42.
Zurück zum Zitat Wagner EF. Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann Rheum Dis. 2010;69 Suppl 1:i86–8.PubMedCrossRef Wagner EF. Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann Rheum Dis. 2010;69 Suppl 1:i86–8.PubMedCrossRef
43.
Zurück zum Zitat Eferl R, Zenz R, Theussl HC, Wagner EF. Simultaneous generation of fra-2 conditional and fra-2 knock-out mice. Genesis. 2007;45(7):447–51.PubMedCrossRef Eferl R, Zenz R, Theussl HC, Wagner EF. Simultaneous generation of fra-2 conditional and fra-2 knock-out mice. Genesis. 2007;45(7):447–51.PubMedCrossRef
44.
Zurück zum Zitat Eferl R, Hasselblatt P, Rath M, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA. 2008;105(30):10525–30.PubMedCrossRef Eferl R, Hasselblatt P, Rath M, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA. 2008;105(30):10525–30.PubMedCrossRef
45.
Zurück zum Zitat •• Maurer B, Busch N, Jungel A et al.: Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009, 120(23):2367–2376. This study showed that mice overexpressing Fra-2 show both fibrotic and vascular characteristics of SSc. In addition, the study showed that Fra-2 is overexpressed in SSc ECs. The authors also demonstrated that blocking Fra-2 in ECs enhances VEGF-mediated angiogenesis in vitro. In all, this study established Fra-2 as an angiogenic transcription factor and demonstrated that Fra-2 transgenic mice may be an excellent model of SSc. PubMedCrossRef •• Maurer B, Busch N, Jungel A et al.: Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009, 120(23):2367–2376. This study showed that mice overexpressing Fra-2 show both fibrotic and vascular characteristics of SSc. In addition, the study showed that Fra-2 is overexpressed in SSc ECs. The authors also demonstrated that blocking Fra-2 in ECs enhances VEGF-mediated angiogenesis in vitro. In all, this study established Fra-2 as an angiogenic transcription factor and demonstrated that Fra-2 transgenic mice may be an excellent model of SSc. PubMedCrossRef
46.
Zurück zum Zitat Reich N, Maurer B, Akhmetshina A, et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum. 2010;62(1):280–90.PubMedCrossRef Reich N, Maurer B, Akhmetshina A, et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum. 2010;62(1):280–90.PubMedCrossRef
47.
Zurück zum Zitat Spyropoulos DD, Pharr PN, Lavenburg KR, et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol. 2000;20(15):5643–52.PubMedCrossRef Spyropoulos DD, Pharr PN, Lavenburg KR, et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol. 2000;20(15):5643–52.PubMedCrossRef
48.
Zurück zum Zitat Liu F, Walmsley M, Rodaway A, Patient R. Fli1 acts at the top of the transcriptional network driving blood and endothelial development. Curr Biol. 2008;18(16):1234–40.PubMedCrossRef Liu F, Walmsley M, Rodaway A, Patient R. Fli1 acts at the top of the transcriptional network driving blood and endothelial development. Curr Biol. 2008;18(16):1234–40.PubMedCrossRef
49.
Zurück zum Zitat Kubo M, Czuwara-Ladykowska J, Moussa O, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003;163(2):571–81.PubMedCrossRef Kubo M, Czuwara-Ladykowska J, Moussa O, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003;163(2):571–81.PubMedCrossRef
50.
Zurück zum Zitat •• Asano Y, Stawski L, Hant F et al.: Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010, 176(4):1983–1998. This novel study expanded on the finding that Fli1 is decreased in SSc ECs by generating mice with Fli1 conditionally knocked out on ECs. The mice exhibited an “SSc-like” phenotype and implicated a role for Fli1 in the vascular pathology of SSc. In addition, the murine model has the potential to serve as a model of SSc vascular disease. PubMedCrossRef •• Asano Y, Stawski L, Hant F et al.: Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010, 176(4):1983–1998. This novel study expanded on the finding that Fli1 is decreased in SSc ECs by generating mice with Fli1 conditionally knocked out on ECs. The mice exhibited an “SSc-like” phenotype and implicated a role for Fli1 in the vascular pathology of SSc. In addition, the murine model has the potential to serve as a model of SSc vascular disease. PubMedCrossRef
Metadaten
Titel
Angiogenesis and Vasculopathy in Systemic Sclerosis: Evolving Concepts
verfasst von
Bradley J. Rabquer
Alisa E. Koch
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Rheumatology Reports / Ausgabe 1/2012
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-011-0219-1

Weitere Artikel der Ausgabe 1/2012

Current Rheumatology Reports 1/2012 Zur Ausgabe

SCLERODERMA (J VARGA, SECTION EDITOR)

Genetics of Systemic Sclerosis: An Update

SCLERODERMA (J VARGA, SECTION EDITOR)

Scleroderma Mimics

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Management of Obstetric Antiphospholipid Syndrome

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Potential Use of Statins in the Treatment of Antiphospholipid Syndrome

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Laboratory Diagnosis of the Lupus Anticoagulant

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.